Garry Schwartz

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Anthony W. Tolcher, Stanton L. Gerson, Christiane Geyer et al. · British Journal of Cancer · 2003 · 366 citations · Full text

Dna Damage, Molecular Biology, Pathology +18

Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer

Eric K. Rowinsky, Garry Schwartz, Jared Gollob et al. · Journal of Clinical Oncology · 2004 · 323 citations · Full text

Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study

Anthony W. Tolcher, Leonel Ochoa, Lisa A. Hammond et al. · Journal of Clinical Oncology · 2003 · 204 citations

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Anthony W. Tolcher, Kim Chi, John G. Kuhn et al. · Clinical Cancer Research · 2005 · 164 citations